TENAX THERAPEUTICS, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
TENAX THERAPEUTICS, INC. (TENX) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $20.41 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-07-31
- TENAX THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $21.19M, a 27.68% increase year-over-year.
- TENAX THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $16.60M, a 501.96% increase year-over-year.
- TENAX THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $2.76M, a 77.57% decline year-over-year.
- TENAX THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $12.29M.
- TENAX THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $2.71M, a 96.81% decline from fiscal 2024.
- TENAX THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $85.06M, a 1009.27% increase from fiscal 2023.
- TENAX THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $7.67M.
- TENAX THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$3.46M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $20.41M 10-Q · filed 2026-07-31 | |||||||
| 2026-03-31 | $21.19M 10-Q · filed 2026-05-12 | |||||||
| 2025-12-31 | $2.71M 10-K · filed 2026-03-10 | |||||||
| 2025-09-30 | $4.52M 10-Q · filed 2025-11-12 | |||||||
| 2025-06-30 | $10.61M 10-Q · filed 2026-07-31 | |||||||
| 2025-03-31 | $16.60M 10-Q · filed 2026-05-12 | |||||||
| 2024-12-31 | $85.06M 10-K · filed 2026-03-10 | |||||||
| 2024-09-30 | $88.52M 10-Q · filed 2025-11-12 | $88.52M 10-Q · filed 2024-11-13 | ||||||
| 2024-06-30 | -$408.00K 10-Q · filed 2025-08-13 | -$408.12K 10-Q · filed 2024-08-13 | ||||||
| 2024-03-31 | $2.76M 10-Q · filed 2025-05-14 | $2.76M 10-Q · filed 2024-05-14 | ||||||
| 2023-12-31 | $7.67M 10-K · filed 2025-03-25 | $7.67M 10-K · filed 2024-03-28 | ||||||
| 2023-09-30 | $9.02M 10-Q · filed 2024-11-13 | |||||||
| 2023-06-30 | $11.27M 10-Q · filed 2024-08-13 | |||||||
| 2023-03-31 | $12.29M 10-Q · filed 2024-05-14 | |||||||
| 2022-12-31 | -$3.46M 10-K · filed 2024-03-28 | |||||||
| 2022-09-30 | -$1.78M 10-Q · filed 2023-11-13 | |||||||
| 2022-06-30 | $1.65M 10-Q · filed 2023-08-14 | |||||||
| 2022-03-31 | -$2.72M 10-Q · filed 2023-05-15 | |||||||
| 2021-12-31 | -$666.32K 10-K · filed 2023-03-31 | |||||||
| 2021-09-30 | $2.10M 10-Q · filed 2022-11-10 | |||||||
| 2021-06-30 | -$4.58M 10-Q · filed 2022-08-11 | |||||||
| 2020-12-31 | $1.34M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |